Research map: Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Mitochondrial dysfunction and applications of mitochondrial-targeted delivery systems in atherosclerosis · 2026 · Related
  3. A Bayesian neural network method for adverse drug reaction signal generation · Andrew M. Bate · 1998 · 1480 citations · Cited by this paper
  4. The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity · 2026 · Related
  5. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index · Jagath Reddy Junutula · 2008 · 1390 citations · Cited by this paper
  6. Non-Viral CRISPR carriers: transient delivery with lasting effects · 2026 · Related
  7. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer · Javier Cortés · 2022 · 1197 citations · Cited by this paper
  8. FEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery · 2026 · Related
  9. Quantitative signal detection using spontaneous ADR reporting · Andrew M. Bate · 2009 · 913 citations · Cited by this paper
  10. Microalgae as novel drug-delivery system for biomedical field · 2026 · Related
  11. Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database · Ana Szarfman · 2002 · 706 citations · Cited by this paper
  12. Folate-targeted gold nanoparticles for doxorubicin delivery in tumor spheroids · 2025 · Related
  13. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial · Sara A. Hurvitz · 2022 · 684 citations · Cited by this paper
  14. Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns · 2026 · Related
  15. Cleavable linkers in antibody–drug conjugates · Jonathan D. Bargh · 2019 · 662 citations · Cited by this paper
  16. Cryopreservation technology for improving the stability of liposomes and its precise drug monitoring in clinical drug research · 2026 · Related
  17. Exploring the next generation of antibody–drug conjugates · Kyoji Tsuchikama · 2024 · 632 citations · Cited by this paper
  18. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial · 2026 · Related
  19. Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death · Chun‐Yan Kong · 2021 · 417 citations · Cited by this paper
  20. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial · Leisha A. Emens · 2020 · 385 citations · Cited by this paper
  21. Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial · Kōichi Goto · 2023 · 325 citations · Cited by this paper
  22. Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals · Ruili Wang · 2025 · 279 citations · Cited by this paper
  23. Optimizing the safety of antibody–drug conjugates for patients with solid tumours · Paolo Tarantino · 2023 · 258 citations · Cited by this paper
  24. Payload diversification: a key step in the development of antibody–drug conjugates · Louise Conilh · 2023 · 252 citations · Cited by this paper
  25. The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development · Raffaele Colombo · 2024 · 229 citations · Cited by this paper
  26. Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) · Hirdesh Uppal · 2014 · 216 citations · Cited by this paper
  27. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems · Paola Maria Cutroneo · 2024 · 204 citations · Cited by this paper
  28. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2 -Positive Metastatic Breast Cancer · Virginia F. Borges · 2018 · 169 citations · Cited by this paper
  29. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates · Paolo Tarantino · 2021 · 166 citations · Cited by this paper
  30. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin · Mario E. Lacouture · 2022 · 156 citations · Cited by this paper
  31. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial · Kohei Shitara · 2024 · 104 citations · Cited by this paper
  32. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity · Haoheng Yan · 2015 · 66 citations · Cited by this paper
  33. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study · M. Martin · 2016 · 54 citations · Cited by this paper
  34. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. · Yelena Yuriy Janjigian · 2022 · 45 citations · Cited by this paper
  35. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database · Pan Ma · 2023 · 44 citations · Cited by this paper
  36. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial · Wen‐Feng Fang · 2025 · 44 citations · Cited by this paper
  37. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer · Adrienne Gropper Waks · 2022 · 41 citations · Cited by this paper
  38. LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) · Jonathan E. Rosenberg · 2022 · 39 citations · Cited by this paper
  39. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database · Viswam Subeesh · 2018 · 37 citations · Cited by this paper

Source: OpenAlex (CC0)